Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($4.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.39) by ($1.18), FiscalAI reports. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million. Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%.
Bolt Biotherapeutics Stock Performance
Shares of NASDAQ:BOLT opened at $3.98 on Wednesday. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.51 and a quick ratio of 3.51. The stock has a market capitalization of $7.64 million, a price-to-earnings ratio of -0.24 and a beta of 1.18. Bolt Biotherapeutics has a fifty-two week low of $3.75 and a fifty-two week high of $7.20. The business’s fifty day moving average price is $4.15 and its two-hundred day moving average price is $4.64.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on BOLT shares. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Rodman & Renshaw started coverage on Bolt Biotherapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Bolt Biotherapeutics has an average rating of “Hold” and a consensus price target of $34.67.
Hedge Funds Weigh In On Bolt Biotherapeutics
Several institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC raised its stake in shares of Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock worth $79,000 after acquiring an additional 2,448 shares during the last quarter. Shay Capital LLC bought a new stake in shares of Bolt Biotherapeutics during the third quarter valued at approximately $85,000. Susquehanna International Group LLP acquired a new stake in shares of Bolt Biotherapeutics in the third quarter valued at approximately $89,000. Finally, Renaissance Technologies LLC boosted its position in Bolt Biotherapeutics by 92.2% in the 4th quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock valued at $301,000 after buying an additional 26,400 shares during the last quarter. Institutional investors own 86.70% of the company’s stock.
Bolt Biotherapeutics Company Profile
Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.
See Also
- Five stocks we like better than Bolt Biotherapeutics
- Paramount’s 30-Film Promise Puts AMC Back in the Box Office Conversation
- DraftKings’ Predictions Push Could Be the Bet That Matters Most
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
